KRAS G12V Mutation: How to Interpret the Finding
KRAS G12V is a codon-12 substitution in which glycine is replaced by valine. It belongs to a family of KRAS alterations that can disrupt normal GTPase regulation, while retaining variant-specific biochemical and tumour-context differences.
Quick Answer
KRAS G12V is a codon-12 substitution in which glycine is replaced by valine. It belongs to a family of KRAS alterations that can disrupt normal GTPase regulation, while retaining variant-specific biochemical and tumour-context differences.
What the Name Encodes
The notation identifies the gene, codon and amino-acid change: glycine at position 12 becomes valine. Codon 12 lies near the KRAS nucleotide-binding region, where mutations can reduce intrinsic GTP hydrolysis.
A persistent active-state population can relay signals to several effectors. That mechanism is useful background, but it does not predict every clinical feature of a KRAS G12V tumour.
Variant-Level Precision
Laboratories may report G12V alongside variant allele fraction and other alterations. Variant allele fraction reflects the tested sample and can be affected by tumour purity and copy-number change.
Do not collapse G12V into a generic 'KRAS positive' label when comparing studies or reports. The precise codon and amino acid are meaningful biological data.
Key Takeaways
- ·G12V is a specific KRAS codon-12 alteration.
- ·It can impair normal KRAS off-switching, but context remains essential.
- ·Keep the exact notation and assay details when discussing a result.
Put these genes in pathway context
Frequently asked questions
What is the key idea in KRAS G12V Mutation: How to Interpret the Finding?
KRAS G12V is a codon-12 substitution in which glycine is replaced by valine. It belongs to a family of KRAS alterations that can disrupt normal GTPase regulation, while retaining variant-specific biochemical and tumour-context differences.
What should be kept with the result or mechanism?
G12V is a specific KRAS codon-12 alteration. It can impair normal KRAS off-switching, but context remains essential. Keep the exact notation and assay details when discussing a result.
References
Continue Reading
KRAS G12C vs G12D: Similar Gene, Different Alterations
2 min read
KRAS G12D Mutation: Biology, Testing and Context
2 min read
KRAS Mutations: Constitutive MAPK Signalling and Targeted Therapy
6 min read
BRAF V600E in Cancer: Mechanism and Targeted Treatment
4 min read
EGFR Exon 19 Deletions: What the Biomarker Means
4 min read
EGFR L858R: Understanding the Exon 21 Mutation
3 min read
Choose your next research step
Move from this explanation into a gene profile, a pathway map, or the next evidence update.
KRAS has 500+ trials currently recruiting on ClinicalTrials.gov. The GeneAnalyses digest summarises the new and changed ones each day.